Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of -24.20% is 22% above its 5-year average of -31.05%, near the high end of its 5-year range (-43.85%–-19.90%).
As of the fiscal period ended Tuesday, June 30, 2026. 9.50% above its 12-month average of -26.74%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q3 FY2026 (2026-06-30): -24.20%.
RETURN ON INVESTED CAPITAL (ROIC)
-24.20%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-26.74%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-31.43%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-31.05%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
-14.28%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
-3.98%
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
+9.50%
CURRENT VS 3Y AVG
+23.02%
CURRENT VS 5Y AVG
+22.06%
CURRENT VS 10Y AVG
-69.41%
CURRENT VS 15Y AVG
-508.26%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-35.64%
median of 838 covered companies
CURRENT VS SECTOR MEDIAN
+32.12%
vs the sector median at left
Enanta Pharmaceuticals, Inc.
Market Cap
$356.36M
Return on Invested Capital (ROIC)
-24.20%
TTM Avg
-26.74%
3Y Avg
-31.43%
5Y Avg
-31.05%
Market Cap
$356.92M
Return on Invested Capital (ROIC)
11.00%
TTM Avg
8.68%
3Y Avg
7.86%
5Y Avg
11.51%
Market Cap
$353.52M
Return on Invested Capital (ROIC)
-84.66%
TTM Avg
-114.58%
3Y Avg
-126.88%
5Y Avg
-126.88%
Market Cap
$357.58M
Return on Invested Capital (ROIC)
-1.84%
TTM Avg
-2.07%
3Y Avg
-43.39%
5Y Avg
-53.01%
Market Cap
$356.07M
Return on Invested Capital (ROIC)
-93.74%
TTM Avg
-188.84%
3Y Avg
-156.74%
5Y Avg
-129.07%
Market Cap
$358.04M
Return on Invested Capital (ROIC)
17.99%
TTM Avg
23.20%
3Y Avg
26.35%
5Y Avg
40.47%
Market Cap
$356.57M
Return on Invested Capital (ROIC)
-27.16%
TTM Avg
-54.52%
3Y Avg
-49.44%
5Y Avg
-51.83%
Market Cap
$353.90M
Return on Invested Capital (ROIC)
-56.73%
TTM Avg
-80.02%
3Y Avg
-65.94%
5Y Avg
-165.76%
Market Cap
$365.67M
Return on Invested Capital (ROIC)
-59.29%
TTM Avg
-166.84%
3Y Avg
-79.03%
5Y Avg
-92.27%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Enanta Pharmaceuticals, Inc. (ENTA) | $356.36M | -24.20% | -26.74% | -31.43% | -31.05% |
| Viemed Healthcare, Inc. (VMD)vs › | $356.92M | 11.00% | 8.68% | 7.86% | 11.51% |
| Turn Therapeutics Inc. (TTRX)vs › | $353.52M | -84.66% | -114.58% | -126.88% | -126.88% |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $357.58M | -1.84% | -2.07% | -43.39% | -53.01% |
| Ocugen, Inc. (OCGN)vs › | $356.07M | -93.74% | -188.84% | -156.74% | -129.07% |
| Embecta Corp. (EMBC)vs › | $358.04M | 17.99% | 23.20% | 26.35% | 40.47% |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $356.57M | -27.16% | -54.52% | -49.44% | -51.83% |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $353.90M | -56.73% | -80.02% | -65.94% | -165.76% |
| Opus Genetics, Inc. (IRD)vs › | $365.67M | -59.29% | -166.84% | -79.03% | -92.27% |
| Relmada Therapeutics, Inc. (RLMD)vs › | $348.23M | -30.78% | -151.81% | -134.98% | -109.65% |
ROIC
-24.2%
ROE
-62.6%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | -24.20% |
| 2026-03-31 | -19.90% |
| 2025-12-31 | -23.06% |
| 2025-09-30 | -32.47% |
| 2025-06-30 | -34.06% |
| 2025-03-31 | -33.18% |
| 2024-12-31 | -33.20% |
| 2024-09-30 | -34.42% |
| 2024-06-30 | -32.95% |
| 2024-03-31 | -34.48% |
| 2023-12-31 | -34.86% |
| 2023-09-30 | -31.57% |
| 2023-06-30 | -28.73% |
| 2023-03-31 | -43.85% |
| 2022-12-31 | -37.63% |
| 2022-09-30 | -35.02% |
| 2022-06-30 | -35.78% |
| 2022-03-31 | -34.78% |
| 2021-12-31 | -31.44% |
| 2021-09-30 | -26.80% |
| 2021-06-30 | -22.40% |
| 2021-03-31 | -18.96% |
| 2020-12-31 | -14.42% |
| 2020-09-30 | -8.84% |
| 2020-06-30 | -3.13% |
| 2020-03-31 | 2.25% |
| 2019-12-31 | 4.39% |
| 2019-09-30 | 7.86% |
| 2019-06-30 | 12.70% |
| 2019-03-31 | 16.31% |
| 2018-12-31 | 18.93% |
| 2018-09-30 | 17.14% |
| 2018-06-30 | 21.40% |
| 2018-03-31 | 14.83% |
| 2017-12-31 | 10.09% |
| 2017-09-30 | 5.29% |
| 2017-06-30 | -12.38% |
| 2017-03-31 | -7.69% |
| 2016-12-31 | -4.34% |
| 2016-09-30 | 7.51% |
| 2016-06-30 | 10.27% |
| 2016-03-31 | 11.69% |
| 2015-12-31 | 23.27% |
| 2015-09-30 | 32.66% |
| 2015-06-30 | 29.30% |
| 2015-03-31 | 50.94% |
| 2014-12-31 | 41.62% |
| 2014-09-30 | 12.60% |
| 2014-06-30 | 12.63% |
| 2014-03-31 | -18.73% |
| 2013-12-31 | -17.04% |
| 2013-09-30 | 8.02% |
| 2013-06-30 | 8.18% |
| 2013-03-31 | 8.46% |
| 2012-12-31 | 67.38% |
| 2012-09-30 | 45.70% |
| 2012-06-30 | 42.17% |
